Tapentadol
Chronic Pain Syndrome
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Thessaly
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06269770CT.gov Tapentadol vs Tramadol in Total Knee Arthroplasty | — | Unknown | — | — | — |
NCT04718116CT.gov Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery | — | Unknown | — | — | — |
NCT01264887CT.gov Tapentadol in Chronic Malignant Tumour Related Pain | — | Terminated | — | — | — |
NCT00986258CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability | — | Terminated | — | — | — |
NCT00983385CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics | — | Completed | — | — | — |
NCT00983073CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic | — | Completed | — | — | — |
NCT00982280CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability. | — | Terminated | — | — | — |
NCT00745069CT.gov Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tapentadol (this asset) | University of Thessaly | Approved | BB · 65 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Jnj-54135419 | Beijing Tiantan Hospital | P4 | BBB |
| Oxycodone | Mayo Clinic | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Tapentadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis | — | P4 | BB · 71 |
| Vertebral Column Disorder | — | P4 | BB · 67 |
| Diabetic Neuropathy | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tapentadol in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/tapentadol-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →